Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014 (2014), Article ID 452685, 6 pages
Research Article

Inhibition of Corneal Neovascularization by Topical and Subconjunctival Tigecycline

1Department of Ophthalmology, Konya Training and Research Hospital, Meram, 42090 Konya, Turkey
2Department of Histology and Embryology, Selcuk University, 42030 Konya, Turkey
3Department of Histology and Embryology, Mevlana University, 42030 Konya, Turkey

Received 30 June 2014; Accepted 28 July 2014; Published 17 August 2014

Academic Editor: Mehmet Borazan

Copyright © 2014 Sertan Goktas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To investigate the effects of topical and subconjunctival tigecycline on the prevention of corneal neovascularization. Materials and Methods. Following chemical burn, thirty-two rats were treated daily with topical instillation of 1 mg/mL tigecycline (group 1) or subconjunctival instillation of 1 mg/mL tigecycline (group 3) for 7 days. Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline. Digital photographs of the cornea were taken on the eighth day after treatment and analyzed to determine the percentage area of the cornea covered by neovascularization. Corneal sections were analyzed histopathologically. Results. The median percentages of corneal neovascularization in groups 1 and 3 were 48% (95% confidence interval (CI), 44.2–55.8%) and 33.5% (95% CI, 26.6–39.2%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group ( and , resp.). Histologic examination of samples from groups 1 and 3 showed lower vascularity than that of control groups. Conclusion. Topical and subconjunctival administration of tigecycline seems to be showing promising therapeutic effects on the prevention of corneal neovascularization. Furthermore, subconjunctival administration of tigecycline is more potent than topical administration in the inhibition of corneal neovascularization.